Congress Panel Warns on China Biotech Licensing Deals

A U.S. commission says Western drug licensing deals with Chinese firms shift capital and know-how toward China.

Updated on Nov. 19, 2026 in Biotech

Congress Panel Warns on China Biotech Licensing Deals

Live Poll

Should the U.S. restrict drug companies from licensing medicines to Chinese firms?

A U.S. congressional commission warned that licensing deals between Western drugmakers and Chinese biotech firms are moving U.S. capital and know-how toward China. The Trump administration has proposed screening requirements or prohibitions on certain deals with Chinese life sciences companies.

Why it matters

The commission found the deals are increasingly based on preclinical data and that upfront payments are arriving earlier in the R&D cycle. The administration cited risks including outbound investments supporting biological weapons or surveillance technology and overdependence on a single country for U.S. supply chains.

The commission analyzed 57 licensing deals between Western drug companies and Chinese firms from the beginning of 2023 through October 2026. Whether this week's Trump-Xi meetings produce biotech agreements or tighter export controls has not been determined.

The players

AstraZeneca

AstraZeneca is a multinational pharmaceutical company headquartered in the United Kingdom that has entered licensing agreements with Chinese biotech firms.

Bristol Myers Squibb

Bristol Myers Squibb is a major American pharmaceutical company that has entered licensing agreements with Chinese biotech firms.

Pfizer

Pfizer is a major American pharmaceutical company that has entered licensing agreements with Chinese biotech firms.

The details

Chinese biotech companies sell licenses to multinational drugmakers for treatments they developed, often earlier in the discovery process, which gives Chinese partners capital and know-how for development and commercialization. In October 2026, China proposed new restrictions on exporting certain technologies, including cell and gene therapy platforms. Under the Trump administration's proposal, equity investments in Chinese firms would be prohibited, while cash-based deals bringing royalties and milestone payments would still be permitted.

Timeline

  1. Beginning of 2023: The 57 analyzed licensing deals period starts.

  2. Last year (2025): The commission posed a Taiwan conflict hypothetical in its report to Congress.

  3. October 2026: China proposed new export restrictions, and the Trump administration proposed screening requirements or prohibitions on certain deals.

  4. October 2026: The analyzed licensing deals period ends.

  5. This week: Meetings between President Trump and Xi Jinping are expected.

Big Picture

The proposed screening requirements would extend U.S. scrutiny of outbound investment into China from equity stakes to licensing deals, while still permitting royalty and milestone-based arrangements. The commission's finding that deals are shifting earlier in the R&D cycle places the policy debate at the preclinical stage of drug development.

Licensing arrangements and funding decisions for new drug candidates could change depending on whether the proposed screening rules are adopted. Patients and clinicians are not directly affected at this stage, as the proposal concerns the structure of corporate deals rather than the availability of treatments.

The takeaway

Investment and partnership flows in biotech are increasingly tied to geopolitics, so readers following drug development should track how screening rules on China-linked deals take shape.

Further reading

For related coverage of research and drug development trends, see Biotech.

Live Poll

Should the U.S. restrict drug companies from licensing medicines to Chinese firms?